Beiersdorf Aktiengesellschaft Stock Timeline

2026 Aug — Half-year results 2026: Derma outperformance; NIVEA turnaround plan

Beiersdorf reported H1 2026 results showing continued Derma strength alongside weakness at NIVEA, announcing an 18-month turnaround and rebalancing plan for NIVEA while adjusting full-year guidance. Investors increasingly viewed the group as operating at two speeds — a growth engine in Derma (Eucerin, Aquaphor) and a cyclical brand-repositioning story in Consumer/NIVEA. Market sentiment shifted toward valuing stability from Derma and patience for NIVEA's recovery.

Group H1 organic sales declined 3.5% to €5.0 billion. EBIT excluding special factors reached €768 million with an EBIT margin of 15.5% [14][11].

2026 Apr — Q1 2026: weak start, Derma up; group organic decline

Q1 2026 results showed Group organic sales declined 4.6%, with Derma organic growth of 8.2% while NIVEA and La Prairie faced headwinds. Management stated results were in line with full-year guidance. This reinforced the market view that Beiersdorf's near-term performance depends on brand mix and timing of NIVEA recovery, with investors emphasizing Derma's resilience and margin contribution.

Group net sales for the quarter were approximately €2.5 billion. Consumer declined 4.7% organically; Derma grew 8.2%; NIVEA net sales fell roughly 7%; La Prairie declined 14.9% [1][5][7].

2026 Mar — Full-year 2025 results: group growth; Derma outperforms

Beiersdorf published FY 2025 results showing Group sales of €9.9 billion with organic growth of 2.4%, with Derma described as outperforming the market. Management had adjusted guidance during the year as end-markets slowed. This confirmed that 2024–25 expansion reflected successful Derma momentum and selective price/mix actions, while investors noted greater execution risk in mass-market NIVEA segments.

2025 (throughout) — Execution and margin focus after post-pandemic normalization

Across 2024–2025 Beiersdorf prioritized margin expansion and portfolio investments in innovation, Derma and premium brands while managing volume pressure in some Consumer markets. Market perception transitioned from pandemic recovery to quality of earnings scrutiny — investors rewarded Derma growth but discounted cyclical Consumer exposure, with valuation narratives splitting between defensive compounder and turnaround candidate. 2025 factsheets show continuing robust EBIT (excluding special factors) and elevated gross cash flow supporting dividends and investments [2][4].

2024 Nov — Annual report 2023: record sales and solid margins

The annual report highlighted 2023 Group sales of €9,447 million and EBIT margin (excluding special factors) of 13.4%, with management emphasizing strategy execution and R&D/brand investment. This reinforced investor view of Beiersdorf as a high-quality consumer healthcare and skincare compounder with predictable cash flows; however, some investors pushed for clearer actions on underperforming areas.

2023 Group sales reached €9,447 million. EBIT excluding special factors was €1,268 million with an EBIT margin of 13.4%. EPS for 2023 was €3.24 [3][4][13].

2023 (through year) — Continued portfolio strength; rising focus on Derma and premium brands

Management emphasized Derma and premiumisation (including La Prairie positioning), with R&D and targeted marketing driving performance; tesa remained steady. Investors increasingly priced Beiersdorf as a balanced portfolio: stable industrial tesa business plus consumer brands with selective upside from Derma/premium execution; some concern existed about margin impact from premium brand investments.

Consumer sales in 2023 reached €7,780 million [4][2].

2022 Mar–Dec — Post-pandemic recovery and strong organic growth

Beiersdorf reported strong 2022 results as markets reopened, with Group sales of €8,799 million and notable organic growth as demand recovered. Management focused on scaling innovations and improving distribution in faster markets. Investor perception moved from pandemic pull-forward volatility to renewed confidence in sustainable demand, with the company seen as re-establishing growth momentum while rebuilding margins.

FY 2022 Group sales reached €8,799 million. EBIT excluding special factors was €1,158 million with an EBIT margin of 13.2% [4][2].

2021 (throughout) — Stabilization after 2020 disruptions

Following 2020 pandemic disruption, 2021 showed stabilization as Beiersdorf communicated recovery plans and ongoing investments in brands and channels. Markets considered Beiersdorf a resilient consumer staples/skin care compounder with steady cash generation and a conservative capital allocation approach with sustained dividends. Some investors remained cautious about near-term topline volatility.

FY 2021 Group sales reached €7,627 million, with gross cash flow and dividend continuity noted in company factsheets [2][9].